E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 8.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10003553 |
E.1.2 | Term | Asthma |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine the safety and tolerability of Captisol-Enabled Budesonide Inhalation Solution (CBIS) delivered via an electronic nebuliser (eFlow, PARI, Munich, Germany) in asthmatic adults 16-60 years of age using clinical endpoints (heart rate, blood pressure), 12-hour overnight urinary cortisol, and adverse events after 2 weeks exposure. |
|
E.2.2 | Secondary objectives of the trial |
To compare the efficacy of CBIS delivered via eFlow to conventional budesonide inhalation suspension (Pulmicort Respules) delivered via a general purpose nebuliser (LC Plus, PARI, Munich, Germany) using methacholine (MCH) challenge test, fractional exhaled nitric oxide (FeNO), clinical asthma symptoms and pulmonary function tests after twice daily treatments for 2 weeks. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1.Age 16 to 60 years, inclusive, at the Screening Visit. 2.Male or female (neither pregnant nor lactating). All female subjects must have a negative urine pregnancy test immediately prior to entry into the study and must be using an acceptable means of birth control. 3.History of asthma for greater than or equivalent to 6 months prior to the Screening Visit as confirmed with clinical signs and symptoms. 4.For steroid-requiring subjects, the dose of inhaled steroid medication received prior to the Screening Visit must be less than or equal to 1000 mcg/day beclomethasone dipropionate or equivalent. 5.History of FEV1 of > 60% of predicted normal values following appropriate withholding of inhaled beta-agonist and corticosteroid medication. Predicted FEV1 will be obtained by using the normal prediction equations of ERS 6.Airway responsiveness to methacholine demonstrated by a provocation concentration causing 10% decrease in FEV1 (PC10) < 4 mg/mL at the Baseline Visit prior to entering Treatment Period 1. 7.Demonstrate ability to use a peak flow meter. 8.Meet two of the following criteria, as recorded by the subject during the Run-In Period on their Diary Cards, for 1 week immediately prior to the Baseline Visit/Treatment Period 1: a. Use of two or more puffs per day of rescue salbutamol for at least 3 days, b. One of the following asthma symptoms: at least one night with sleep disturbance, at least 3 days with asthma symptoms. 9.Must otherwise be healthy as judged by general physical examination, medical history and routine clinical laboratory screening. 10.Provide written informed consent (parent or legal guardian) and, as appropriate, subject assent. 11.Willing to discontinue current treatment and able to attend scheduled visits and complete the entire study.
|
|
E.4 | Principal exclusion criteria |
1. History of life-threatening asthma. This category includes those subjects with a history of systemic corticosteroid treatment within 3 months of study entry or near-fatal asthma requiring intubation or a hospitalisation or an Urgent Care Facility visit for asthma in the past year. 2. Current evidence or history of any clinically significant disease or abnormality. “Clinically significant” is defined as any disease that, in the opinion of the Investigator, would put the subject at risk through study participation, or which would affect the outcome of the study. 3. History of concomitant lung disease. 4. An upper or lower respiratory tract infection within 4 weeks prior to the Screening Visit. 5. If more than 12 puffs of salbutamol, per day, are used. 6. Current evidence or history of hypersensitivity or idiosyncratic reaction to inhaled budesonide or any medication. 7. Receipt of an investigational drug within 30 days of the Screening Visit.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Safety: The primary safety outcome is change in overnight urinary cortisol from baseline. The other safety variables will include the changes in vital signs, physical examination findings, and the incidence of treatment-emergent AEs during the Treatment Period.
Efficacy: The primary efficacy outcome is change in PC10 from baseline (pooled value of post-Run-in and post-Washout Period values), following methacholine challenge. The other efficacy variables will include the changes in asthma symptom scores, pulmonary function tests, and airway and alveolar nitric oxide (FeNO).
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
|
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the trial will be the last visit of the last patient. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 8 |
E.8.9.2 | In all countries concerned by the trial days | 0 |